Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032388 | 0.81 | PDE2A (0.53) | PDE2AALDH1A1KDM1ARCOR1TSHR | |
| SCHEMBL20381850 | 0.80 | PDE2A (0.53) | PDE2AALDH1A1TSHRLMNAHRH3 | |
| SCHEMBL12318715 | 0.79 | PDE2A (0.56) | PDE2AALDH1A1TSHRLMNAHRH3 | |
| SCHEMBL14233628 | 0.79 | PDE2A (0.56) | PDE2AALDH1A1TSHRLMNAHRH3 | |
| SCHEMBL1676518 | 0.79 | PDE2A (0.54) | PDE2AALDH1A1TSHRL3MBTL1 | |
| SCHEMBL646645 | 0.78 | PDE2A (0.49) | PDE2AALDH1A1L3MBTL1SLC7A5 | |
| SCHEMBL11215946 | 0.78 | PDE2A (0.49) | PDE2AALDH1A1TSHRL3MBTL1SLC7A5 | |
| SCHEMBL1729820 | 0.78 | PDE2A (0.50) | PDE2AALDH1A1KDM1ARCOR1TSHR | |
| SCHEMBL1727845 | 0.78 | PDE2A (0.50) | PDE2AALDH1A1KDM1ARCOR1TSHR | |
| SCHEMBL4542016 | 0.78 | PDE2A (0.54) | PDE2AALDH1A1TSHRLMNAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| CN-103201261-A | Lactam derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2013-07-10 | — | — | CN | disclosed |
| US-20130150377-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHIONOGI & CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-8324249-B2 | Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-12-04 | — | — | US | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20110136833-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHINOGI & CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150377-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | TRPV1, CACNA1A, CACNA1E | PDE2A 677/4885ALDH1A1 2698/4885KDM1A 2506/4885 |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | PDE2A 2296/4885ALDH1A1 2282/4885KDM1A 1270/4885 |
| US-20110136833-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | TRPV1, CACNA1A, CACNA1E | PDE2A 677/4885ALDH1A1 2698/4885KDM1A 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.